|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- | New P2 trial: WIRMS: Worms for Immune Regulation of Multiple Sclerosis (clinicaltrials.gov) - Nov 9, 2011
P2, N=72, Recruiting, Sponsor: University of Nottingham
- trichuris suis ova (CNDO-201) / Fortress
Trial completion: TRIMS A: Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study (clinicaltrials.gov) - Nov 8, 2011
P2, N=10, Completed, Sponsor: Rigshospitalet, Denmark
Not yet recruiting --> Completed
- New P1 trial, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - Nov 2, 2011
P1, N=400, Recruiting, Sponsor: Carmel Medical Center
- ||||||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Avonex China: Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 2, 2011
P3, N=60, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: TYNERGY: Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (clinicaltrials.gov) - Nov 2, 2011
P=N/A, N=60, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Completed
- | GSK 2018682 / GSK
New P1 trial: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (clinicaltrials.gov) - Nov 2, 2011
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- Betaseron (IFN-?-1b) / Bayer
Enrollment change, Drug adherence, Adherence: POR-BetaPlus: Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=10, Completed, Sponsor: Bayer
Recruiting --> Completed N=20 --> 10
- Betaseron (IFN-?-1b) / Bayer
Trial completion, Drug adherence, Adherence: POR-BetaPlus: Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=10, Completed, Sponsor: Bayer
N=20 --> 10 Active, not recruiting --> Completed
- Trial completion: Effects of Training on Central Auditory Function in Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2011
P=N/A, N=158, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Zinbryta (daclizumab) / Biogen, AbbVie
New P3 trial: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2011
P3, N=135, Active, not recruiting, Sponsor: Biogen Idec
- Farydak (panobinostat) / Secura Bio
New P2 trial: A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 25, 2011
P2, N=25, Recruiting, Sponsor: Kristie Blum
- | Nanocort (liposomal prednisolone) / Galapagos, Enceladus
Clinical: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 23, 2011
P2, N=90, Suspended, Sponsor: Galapagos NV
Recruiting --> Completed Recruiting --> Suspended
- Trial completion: Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) (clinicaltrials.gov) - Oct 23, 2011
P1/2, N=10, Completed, Sponsor: University of Cambridge
Recruiting --> Suspended Active, not recruiting --> Completed
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
New P2 trial: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 20, 2011
P2, N=232, Active, not recruiting, Sponsor: GlaxoSmithKline
- ||||| New P4 trial: MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia (clinicaltrials.gov) - Oct 19, 2011
P4, N=180, Completed, Sponsor: Biogen Idec
- glatiramer acetate / Generic mfg.
New P4 trial: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (clinicaltrials.gov) - Oct 18, 2011
P4, N=10, Completed, Sponsor: University of Southern California
- Trial completion: SHSCL: Sex Hormones & Serum Sclerostin Level (clinicaltrials.gov) - Oct 18, 2011
P=N/A, N=45, Completed, Sponsor: Bagcilar Training and Research Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- | New P4 trial: Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate (clinicaltrials.gov) - Oct 17, 2011
P4, N=40, Completed, Sponsor: Brown, Theodore R., M.D., MPH
- Enrollment closed: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Oct 17, 2011
P=N/A, N=20, Active, not recruiting, Sponsor: University of Florida
Recruiting --> Completed Recruiting --> Active, not recruiting
- New P1/2 trial, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 16, 2011
P1/2, N=10, Not yet recruiting, Sponsor: Ageless Regenerative Institute
- New P2 trial: Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (clinicaltrials.gov) - Oct 12, 2011
P2, N=18, Terminated, Sponsor: Louisiana State University Health Sciences Center in New Orleans
- | phenytoin / Generic mfg.
New P2 trial: Neuroprotection With Phenytoin in Optic Neuritis (clinicaltrials.gov) - Oct 11, 2011
P2, N=90, Recruiting, Sponsor: University College, London
- | Kinaction (masitinib) / AB Science
New P2 trial: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 5, 2011
P2, N=35, Completed, Sponsor: AB Science
- New P2 trial: Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE (clinicaltrials.gov) - Oct 5, 2011
P2, N=20, Recruiting, Sponsor: University at Buffalo Neurosurgery
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Adherence: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (clinicaltrials.gov) - Oct 5, 2011
P=N/A, N=256, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New P1/2 trial: T Cell Vaccination in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 4, 2011
P1/2, N=30, Completed, Sponsor: Hadassah Medical Organization
- ||| Trial completion, HEOR: A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment (clinicaltrials.gov) - Sep 29, 2011
P=N/A, N=600, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=300, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Completed
- || New P3 trial: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Sep 26, 2011
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Safety and Tolerability of Rituximab in Neuromyelitis Optica (clinicaltrials.gov) - Sep 25, 2011
P1, N=20, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
New P2/3 trial: Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 22, 2011
P2/3, N=90, Recruiting, Sponsor: Biogen Idec
- Tracleer (bosentan) / J&J, Roche
Enrollment change: Early Therapy of Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=10, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed N=20 --> 10
- ||| dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
New P1 trial: Dexpramipexole SAD/MAD Study (clinicaltrials.gov) - Sep 21, 2011
P1, N=63, Completed, Sponsor: Biogen Idec
- Tracleer (bosentan) / J&J, Roche
Trial completion: Early Therapy of Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=10, Completed, Sponsor: Medical University of Graz
N=20 --> 10 Recruiting --> Completed
- New P2 trial: Low Protein Diet in Patients With Collagen VI Related Myopathies (clinicaltrials.gov) - Sep 20, 2011
P2, N=8, Completed, Sponsor: Istituto Ortopedico Rizzoli
- | dalfampridine / Generic mfg.
New P2 trial: Dalfampridine for Imbalance in Multiple Sclerosis (clinicaltrials.gov) - Sep 19, 2011
P2, N=24, Active, not recruiting, Sponsor: Oregon Health and Science University
- ||||| New P4 trial: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Sep 18, 2011
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
- Trial termination: PLACATE-MS: Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS (clinicaltrials.gov) - Sep 15, 2011
P2, N=20, Terminated, Sponsor: University of Rochester
Recruiting --> Completed Enrolling by invitation --> Terminated; funding stopped due to slow enrollment.
- ||||||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Trial completion: CONFIRM: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 14, 2011
P3, N=1232, Completed, Sponsor: Biogen Idec
Enrolling by invitation --> Terminated; funding stopped due to slow enrollment. Active, not recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
New P2 trial: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 11, 2011
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| PF-00489791 / Pfizer
Trial completion: PF-00489791 For The Treatment Of Raynaud's (clinicaltrials.gov) - Sep 11, 2011
P2, N=246, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=50, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: FREEDOMS II: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 6, 2011
P3, N=1083, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Clinical: Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (clinicaltrials.gov) - Sep 5, 2011
P2/3, N=30, Terminated, Sponsor: Neurologique Foundation, Inc.
Active, not recruiting --> Completed Recruiting --> Terminated; Study reached halfway point in approximately one year time period and was halted to analyze data.
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Clinical: Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (clinicaltrials.gov) - Sep 5, 2011
P2/3, N=30, Terminated, Sponsor: Neurologique Foundation, Inc.
Recruiting --> Terminated; Study reached halfway point in approximately one year time period and was halted to analyze data. N=63 --> 30
- Trial completion: Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b (clinicaltrials.gov) - Sep 5, 2011
P2, N=28, Completed, Sponsor: University Hospital Inselspital, Berne
N=63 --> 30 Active, not recruiting --> Completed
- escitalopram / Generic mfg.
Trial completion: Escitalopram (Lexapro) for Depression MS or ALS (clinicaltrials.gov) - Sep 5, 2011
P3, N=13, Completed, Sponsor: University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=85, Completed, Sponsor: University at Buffalo
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| diazoxide (ATH-012) / Neurotec Pharma, Advancell
New P2a trial: A Phase IIa Study of NT-KO-003 for Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2011
P2a, N=99, Completed, Sponsor: Neurotec Pharma
- New P2 trial, Preclinical: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2011
P2, N=50, Terminated, Sponsor: GlaxoSmithKline